Caribou Biosciences(US:CRBU)2026-03-05 21:07Financial Performance - Caribou reported licensing and collaboration revenue of $3.9 million for Q4 2025 and $11.2 million for the full year 2025, up from $2.1 million and $10.0 million in the same periods of 2024, respectively [6]. - Caribou Biosciences reported licensing and collaboration revenue of $3,941,000 for Q4 2025, a 90% increase from $2,077,000 in Q4 2024 [27]. - The net loss for Q4 2025 was $26,488,000, compared to a net loss of $35,490,000 in Q4 2024, representing a 25% improvement [27]. - Caribou reported a GAAP net loss of $26.5 million, or $0.28 per share, for Q4 2025, and a full year net loss of $148.1 million, or $1.59 per share, compared to a net loss of $35.5 million, or $0.39 per share, and $149.1 million, or $1.65 per share, in 2024 [10]. - Non-GAAP net loss for full year 2025 was $126.8 million, or $1.36 per share, compared to a non-GAAP net loss of $149.1 million, or $1.65 per share, in 2024, excluding $21.3 million of non-cash impairment charges [11]. - Non-GAAP net loss for the year ended December 31, 2025 was $126,817,000, compared to $149,105,000 in 2024, reflecting a 15% improvement [28]. - The company reported a net loss per share of $0.28 for Q4 2025, an improvement from $0.39 in Q4 2024 [28]. Expenses - R&D expenses decreased to $23.8 million for Q4 2025 and $109.4 million for the full year 2025, compared to $30.5 million and $130.2 million in 2024, primarily due to workforce reduction and strategic pipeline prioritization [7]. - General and administrative expenses were $8.6 million for Q4 2025 and $37.9 million for the full year 2025, down from $10.5 million and $46.5 million in 2024, mainly due to lower legal and personnel-related expenses [8]. - Total operating expenses for Q4 2025 were $32,394,000, down 21% from $40,952,000 in Q4 2024 [27]. - Research and development expenses decreased to $23,815,000 in Q4 2025 from $30,464,000 in Q4 2024, a reduction of 22% [27]. Assets and Equity - As of December 31, 2025, Caribou had $142.8 million in cash, cash equivalents, and marketable securities, down from $249.4 million as of December 31, 2024, expected to fund operations into 2H 2027 [12]. - Total assets decreased to $175,367,000 as of December 31, 2025, down from $313,313,000 as of December 31, 2024 [25]. - Total stockholders' equity fell to $122,175,000 in 2025 from $252,951,000 in 2024, a decline of 52% [25]. - Caribou's total liabilities decreased to $53,192,000 in 2025 from $60,362,000 in 2024, a reduction of 18% [25]. Clinical Trials and Developments - The vispa-cel ANTLER phase 1 trial demonstrated efficacy and durability comparable to autologous CAR-T therapy, with longer follow-up data expected later in 2026 [2]. - Caribou initiated dose expansion of the CB-011 CaMMouflage phase 1 clinical trial for multiple myeloma, with initial data anticipated in 2026 [2]. - The company is in ongoing engagement with the FDA regarding the pivotal trial design for vispa-cel in second-line large B cell lymphoma [5]. - Non-recurring, non-cash impairment charges for the year ended December 31, 2025, totaled $21.3 million, related to strategic pipeline prioritization and an impairment of a stock investment [9]. Share Information - The weighted-average common shares outstanding increased to 94,536,493 in Q4 2025 from 91,161,148 in Q4 2024 [28].